Catalog No.
Product Name
Application
Product Information
Citations
-
CXCR2/CCR7 Antagonist
CCR7 antagonist 1 is a potent dual antagonist of CXCR2 and CCR7, exhibiting an IC50 of 11.02 μM for CXCR2 and 0.43 μM for CCR7. This compound demonstrates significant inhibition of chemokine receptor signaling, making it valuable for studying inflammatory responses and immune system modulation. Its application spans various fields, including cancer research and autoimmune disease studies, where targeting these receptors can provide insights into disease mechanisms and potential therapeutic strategies. -
CCR7 Antagonist
SLW131 is a potent CCR7 antagonist, demonstrating a high affinity with a Ki value of 9.85 nM. This compound effectively inhibits CCL19-induced Go protein activation with an IC50 of 29.4 μM, as well as β-arrestin2 recruitment with an IC50 of 6.0 μM. SLW131 also disrupts CCL19-induced morphological alterations in primary bone marrow-derived dendritic cells and impedes CCR7-mediated migration in mouse CD4+ T cells, making it a valuable tool for research in immune response and cell signaling pathways. -
CCR5 Antagonist
PF-232798 is an orally bioavailable antagonist of the CCR5 receptor, primarily known for its role in HIV entry into cells. By blocking CCR5, PF-232798 demonstrates efficacy in inhibiting HIV replication and offers potential applications in antiviral research. Its selective activity makes it a valuable tool for studying HIV pathogenesis and developing new therapeutic strategies against the virus. -
CCR5 Antagonist
CCR5 antagonist 2 is a potent inhibitor of the CCR5 receptor, exhibiting an IC50 of 8.34 nM. This compound demonstrates broad-spectrum anti-HIV-1 activity and can be utilized in research focused on HIV pathogenesis and therapy development. Its mechanism of action makes it a valuable tool for studies aimed at blocking viral entry and understanding the role of CCR5 in immune response. -
CCR5 Inhibitor
CMPD167 is a selective CCR5 inhibitor that exerts its antiviral effects by blocking the CCR5 receptor, which is critical for the entry of certain viruses into host cells. This compound demonstrates potent antiviral activity in vitro, making it a valuable tool for research on viral infections, particularly in studies related to HIV. CMPD167 can facilitate investigations into CCR5-related pathways and the development of therapeutic strategies targeting viral entry mechanisms. -
CCR5 inhibitor
CB-0821 is a high-affinity CCR5 inhibitor with a Ki value of 0.04 nM. It effectively binds to the hydrophobic pocket of the CCR5 protein, disrupting the interactions between viral proteins and CCR5, which inhibits viral entry into cells. This compound is poised for use in anti-HIV research applications, facilitating studies on viral tropism and potential therapeutic strategies. -
CCR5 Antagonist
E913 is a selective antagonist of the CCR5 receptor, effectively inhibiting the binding of macrophage inflammatory protein-1alpha (MIP-1alpha) to CCR5 with an IC50 of 0.002 μM. This compound also blocks MIP-1alpha-induced cellular Ca2+ mobilization, demonstrating an IC50 of 0.02 μM. E913 significantly suppresses the replication of both laboratory and primary R5 HIV-1 strains, including multidrug-resistant variants, with IC50 values ranging from 0.03 to 0.06 μM. This reagent is valuable for research into HIV-1 infection and related mechanisms of immune response. -
CCR5 Antagonist
GSK-214096 is a selective CCR5 antagonist that inhibits HIV-1 entry through the blockade of the virus's glycoprotein 120 (gp120). By targeting the CCR5 co-receptor, this compound plays a critical role in interrupting HIV-1 infection pathways. It is valuable for research applications focused on HIV-1 biology and therapeutic discovery. -
HCCR2 antagonist
INCB 3284 dimesylate is a potent, selective hCCR2 antagonist that exhibits potenct antagonism against monocyte chemoattractant molecule binding to hCCR2 and chemotaxis activity. -
non-peptide CCR1 antagonist
BX471 hydrochloride (ZK-811752 hydrochloride) is a potent, selective non-peptide CCR1 antagonist with Ki of 1 nM for human CCR1, and exhibits 250-fold selectivity for CCR1 over CCR2, CCR5 and CXCR4. -
CKLF1/CCL17 inhibitor
CKLF1-C19 is the C-terminal peptide of human chemokine-like factor 1 (CKLF1). CKLF1-C19 interacts with CCR4, and inhibits chemotaxis induced by both CKLF1 and CCL17. CKLF1-C19 can suppress allergic lung inflammation via inhibiting chemotaxis mediated by CCR3 and CCR4. -
CCR2 Antagonist
INCB8761(PF-4136309) is a potent, selective, and orally bioavailable CCR2 antagonist. -
CCR4 antagonist
GSK2239633A is a CC-chemokine receptor 4 (CCR4) antagonist, which inhibits the binding of [125I]-TARC to human CCR4 with a pIC50 of 7.96??0.11. -
CCR 2 antagonist
Teijin compound 1 is a specific CCR 2 antagonist with IC50s of 24 and 180 nM in chemotaxis and binding assay, respectively. -
CCR2/CCR5 inhibitor
Cenicriviroc is an experimental drug candidate for the treatment of HIV infection.Cenicriviroc is an inhibitor of CCR2 and CCR5 receptors, allowing it to function as an entry inhibitor which prevents the virus from entering into a human cell. -
CCR2/5 receptors inhibitor
Cenicriviroc, also known as TAK-652 and TBR-652, is an inhibitor of CCR2 and CCR5 receptors, allowing it to function as an entry inhibitor which prevents the virus from entering into a human cell. CAS: 199673-74-0(LY 334370 hydrochloride); 182563-08-2 (LY 334370 Free Base) -
CCR2/CCR5 antagonist
BMS-813160 is a potent and selective CCR2/CCR5 antagonist with potential immunomodulating and antineoplastic activities. -
CCR4 antagonist
CCR4 antagonist 2 (Compound 31) is a novel potent, orally bioavailable small molecule antagonists of CC chemokine receptor 4 (CCR4) that inhibits Treg trafficking into the Tumor Microenvironment without suppressing the number of Treg in healthy tissues. -
CCR8 agonist
ZK-756326 is a potent, selective and non-peptide CCR8 chemokine receptor agonist. ZK 756326 inhibited the binding of the CCR8 ligand I-309 (CCL1), with an IC(50) value of 1.8 μM. -
CCR2 antagonist
CCR2-RA-[R] is an allosteric antagonist of the C-C chemokine receptor type 2 (CCR2) with an IC50 of 103 nM. -
CCR2 antagonist
RS102895 hydrochloride is a potent CCR2 antagonist, with an IC50 of 360 nM, and shows no effect on CCR1. -
CCR5 antagonist
CCR5 antagonist 1 is a CCR5 antagonist which can inhibit HIV replication extracted from WO 2004054974 A2. -
CCR2 antagonist
CCR2 antagonist 3 is a chemokine receptor 2 (CCR2) antagonist. -
CCR2 /CCR5 dual antagonist
PF-04634817 is an orally administered CCR2 and CCR5 chemokine receptor antagonist, for the treatment of diabetic nephropathies and diabetic macular oedema. -
CCR2 antagonist
CCR2 antagonist 1 is a high-affinity and long-residence-time CCR2 antagonist, with a Ki of 2.4 nM. -
CCR2 antagonist
PF-4136309 is a potent, selective, and orally bioavailable CCR2 antagonist, with IC50s of 5.2 nM, 17 nM and 13 nM for human, mouse and rat CCR2. -
CCR5 antagonist
Vicriviroc maleate is a CCR5 antagonist with IC50 of 0.91 nM in clinical development for the treatment of HIV-1.
